Ubs Group Ag Roivant Sciences Ltd. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding ROIV
# of Institutions
308Shares Held
496MCall Options Held
989KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$870 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$843 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$813 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$431 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$358 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.59B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...